Effects of Photobiomodulation on cognitive, physical, and cerebral neurovascular function in Parkinson’s disease

Parkinson’s disease (PD) is increasingly prevalent, affecting ~170 per 100,000 Canadians annually. Currently, there is no cure for PD, warranting the investigation of potential new therapeutics. Photobiomodulation (PBM) is a low-level light therapy that has been proposed as an alternative treatment for neurodegenerative diseases, such as PD. However, there is a lack of data regarding the efficacy of PBM on individuals with PD, specifically cerebrovascular function. Accordingly, our study aims to attain pilot data to complete a full randomized control trial. The objectives of the study are to determine the effects of PBM in patients with PD on: (1) cognitive function;
(2) motor function; and (3) cerebrovascular function. In our double-blind cross-over study, participants will be assigned to both the treatment and placebo groups. To determine whether there is a difference in receiving PBM compared to placebo, participants will undergo a series of cognitive, neurovascular, cerebrovascular, and physical assessments to determine their respective functional status. These data will provide insight on the potential use of PBM as an alternative therapy for PD.

Faculty Supervisor:

Anthony Bain

Student:

Partner:

Parkinson Society Southwestern Ontario

Discipline:

Life Sciences

Sector:

Other services (except public administration)

University:

University of Windsor

Program: